| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 3603.3 | 3736.8 | 3143.8 |
| Other income | 200.1 | 143.1 | 146.0 |
| Total income | 3803.4 | 3879.9 | 3289.7 |
| Profit before exceptional items & tax | 557.8 | 834.0 | 396.3 |
| Exceptional items | -135.0 | -52.8 | 0.0 |
| Profit before tax | 422.9 | 781.2 | 396.3 |
| Net profit | 236.5 | 636.0 | 305.9 |
| Operating margin | 11.1% | 20.1% | 12.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -22.70% |
|---|---|
| Net profit, quarter on quarter | -62.80% |
| Revenue, year on year | +14.60% |
BSE results filing, NSE: ALKEM. Figures extracted from the filing.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,274.00
- Market cap
- ₹63,059 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 29.2×Sector 50.4×
- Promoter holding
- 49.70%-1.50% QoQ
- FII holding
- 10.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Management Change
Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.
Alkem Laboratories Debt & Borrowing: ₹593.5 Cr
Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.
- Value
- ₹593.5 Cr
Alkem Laboratories Product Launch
Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.
Alkem Laboratories Management Change
Alkem Laboratories has appointed Dr. Shubhadeep Sinha as a Senior Management Personnel, effective September 15, 2026. This appointment falls under standard senior management disclosures.
Alkem Laboratories Product Launch
Alkem launched Renocia Exo, a patented exosome-based hair growth serum. It expands the company's dermatology portfolio with a new follicle-support therapy.
Alkem Laboratories Investor Presentation: Key Takeaways
Alkem reported Q1FY27 revenue of INR 3,740cr, up 11% YoY. India sales grew 10.3%, while International jumped 16%. EBITDA margin stood at 20.5%. Net profit declined 21.7% due to taxation.
- Call
- Guides 12% growth